In vitro  and  in vivo  effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

Marta Michalska; Susanne Schultze-Seemann; Lioudmila Bogatyreva; Dieter Hauschke; Ulrich Wetterauer; Philipp Wolf

doi:10.18632/oncotarget.8001

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

Marta Michalska _, Susanne Schultze-Seemann, Lioudmila Bogatyreva, Dieter Hauschke, Ulrich Wetterauer and Philipp Wolf

PDF | HTML | How to cite

Oncotarget. 2016; 7:22531-22542. https://doi.org/10.18632/oncotarget.8001

Metrics: PDF 1828 views | HTML 2430 views | ?

Abstract

Marta Michalska1, Susanne Schultze-Seemann1, Lioudmila Bogatyreva2, Dieter Hauschke2, Ulrich Wetterauer1, Philipp Wolf1

1Department of Urology, Medical Center, University of Freiburg, Freiburg, Germany

2Institute for Medical Biometry and Statistics, Medical Center, University of Freiburg, Freiburg, Germany

Correspondence to:

Philipp Wolf, e-mail: [email protected]

Keywords: prostate cancer, PSMA, immunotoxin, docetaxel, chemotherapy

Received: November 26, 2015 Accepted: February 23, 2016 Published: March 9, 2016

ABSTRACT

Docetaxel (DOC) is used for the first-line treatment of castration resistant prostate cancer (CPRC). However, the therapeutic effects are limited, only about one half of patients respond to the therapy and severe side effects possibly lead to discontinuation of treatment. Therefore, actual research is focused on the development of new DOC-based combination treatments.

In this study we investigated the antitumor effects of a recombinant immunotoxin targeting the prostate specific membrane antigen (PSMA) in combination with DOC in vitro and in vivo. The immunotoxin consists of an anti-PSMA single chain antibody fragment (scFv) as binding and a truncated form of Pseudomonas aeruginosa Exotoxin A (PE40) as toxin domain. The immunotoxin induced apoptosis and specifically reduced the viability of androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer cells. A synergistic cytotoxic activity was observed in combination with DOC with IC₅₀ values in the low picomolar or even femtomolar range. Moreover, combination treatment resulted in an enhanced antitumor activity in a C4-2 SCID mouse xenograft model. This highlights the immunotoxin as a promising therapeutic agent for a future DOC-based combination therapy of CPRC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8001

Publication Alerts

Research Papers:

In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

Abstract